Skip to main content
. 2017 May 24;28(7):677–701. doi: 10.1097/CAD.0000000000000513

Table 3.

Renal impairment studies performed for 29 small molecule oncology drugs approved by the Food and Drug Administration from 2010 through the first quarter of 2015

graphic file with name cad-28-677-g004.jpg